Jupiter Life Line Hospitals Ltd (JLHL), which hit the street this week to raise Rs 869 crore via an IPO, has got favourable analyst calls, with some recommending subscribing for listing gains, and others suggesting buying for long-term growth.
The support for the company’s initial public offer stems from its strong financial and operational performance, dominant regional presence, reasonable valuations when compared to peers, and growth outlook.
Jupiter Life Line Hospitals is a multi-speciality tertiary and quaternary healthcare provider in the Mumbai Metropolitan Area (MMR) and western region of India, with three hospitals under its umbrella. The company’s public issue opened for subscription on September 6, and was subscribed 87 percent at the end of day one of bidding, with strong interest from non-institutional and retail investors.
Regional and operational dominance
According to a CRISIL report, the company’s Thane and Indore hospitals are among the few hospitals in the western region of India to provide neuro-rehabilitation services through a dedicated robotic and computer-assisted neurorehabilitation centre. Additionally, it operates one of the few multi-organ transplant centres in Thane.
The company currently operates hospitals under the “Jupiter” brand in Thane, Pune, and Indore, with a total operational bed capacity of 1,194 beds. It has delivered high operational and financial performance through robust patient volumes, cost efficiency and diversified revenue streams across hospitals.
Source Link: Jupiter Life Line Hospitals IPO offers growth, market dominance. Should you subscribe?